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Cadmium is a ubiquitous environmental pol-
lutant of increasing worldwide concern. Food
crops grown on Cd-containing soils or on
soils naturally rich in this metal constitute a
major source of nonworkplace exposure to Cd
other than exposure from cigarette smoking
[International Programme on Chemical Safety
(IPCS) 1992; Jarup et al. 1998; Satarug et al.
2000a, 2003; World Health Organization
(WHO) 1989]. Approximately 0.001% of Cd
in the body is excreted per day, mostly in
urine. Such extremely slow excretion rate of
Cd is due to a lack of an active biochemical
mechanism for elimination coupled with renal
reabsorption. Cd accumulation occurs in vari-
ous tissues and organs, with the most extensive
accumulation occur in kidney cortex (IPCS
1992; Jarup et al. 1998; WHO 1989). Renal
Cd concentration is strongly age related, and
usually it reaches a plateau at 50 years of age,
consonant with an age-related degeneration of
kidney reabsorption function (Satarug et al.
2002). The average concentration of Cd in
liver and kidney cortex in Australian subjects
41–50 years of age was 1.4 µg/g liver wet
weight (ww) and 26 µg/g kidney cortex ww
(Satarug et al. 2002). The corresponding mean
concentration was 2 µg/g liver ww and 70 µg/g
kidney cortex ww in Japanese subjects
(Yoshida et al. 1998) and 1.6 µg/g liver ww
and 41 µg/g kidney cortex ww in Canadian
subjects (Benedetti et al. 1999).
The manifestations of Cd nephrotoxicity,
including proteinuria, calciuria, amino-
aciduria, glycosuria, and tubular necrosis, have
been detected at renal Cd concentrations of
≥ 50 µg/g tissue ww. Cd persists in the kidneys
of humans for many years (half-life of
30 years). This provides an opportunity for Cd
toxicity to occur with no additional exposure,
when the previously bound (nontoxic) Cd is
displaced and released (Satarug et al. 2000b).
An increase in mortality risk by 40–100% has
been noted for individuals with signs of Cd-
linked nephropathy (Arisawa et al. 2001; Jarup
et al. 1998). In addition to its well-known
nephrotoxity, chronic exposure to low-level
Cd has been associated with a number of
pathologies, such as end-stage renal failure,
early onset of diabetic renal complications,
osteoporosis, deranged blood pressure regula-
tion, and increased cancer risk (IARC 1993;
IPCS 1992; Jarup et al. 1998; Nakagawa and
Nishijo 1996).
In this commentary we highlight clinically
relevant outcomes of chronic exposure to envi-
ronmental Cd and discuss international food
legislation. We also comment on recent studies
involving Cd dose (burden)–response analysis.
Most of these studies, however, have not
included Cd intake data. In such instances, we
applied a toxicokinetic model of Cd in an
attempt to relate Cd burden (urinary Cd excre-
tion) to Cd intake and observed adverse health
outcomes. This model predicts that a Cd level
of 50 µg/g kidney cortex ww, corresponding
to urinary Cd excretion of 2–4 µg/day, may
be attained after 50 years of intake of about
1 µg Cd/kg body weight/day (Buchet et al.
1990). This ﬁgure is equivalent to the current
guideline for safe intake levels of dietary Cd
(WHO 1993).
Provisional Tolerable Weekly
Intake for Cd
In 1989, the Food and Agriculture
Organization/World Health Organization
(FAO/WHO) Joint Expert Committee on
Food Additives (JECFA) set the provisional
tolerable weekly intake (PTWI) for Cd at
7µ g/kg body weight/week, corresponding to
1 µg/kg body weight/day, or 70 µg/day
(WHO 1989). However, Cd-linked kidney
toxicity occurred in higher-than-expected fre-
quencies in human populations whose dietary
Cd intakes were well within the current
PTWI, suggesting that the current PTWI is
not sufﬁciently restrictive to protect the gen-
eral population. At its 41st meeting in 1993,
the JECFA recognized that the model on
which the PTWI for Cd was based did not
include a safety factor, and thus the PTWI
for Cd has a very modest safety margin
between exposure in normal diet and expo-
sure that produces adverse effects (WHO
1993). The PTWI or the tolerable daily
intake (TDI) for a contaminant is usually
derived from the lowest observed adverse
effect level (LOAEL) in the most sensitive
species, using an uncertainty factor of 100,
provided that the relative susceptibility of
humans and animals is unknown at the time
of derivation of the tolerable intake. The
PTWI or TDI value needs to be substantiated
by experimental data, and a larger uncertainty
factor is applied when a LOAEL is the point
of departure.
International Food Legislation
The Joint FAO/WHO Codex Alimentarius
Commission was established in the early
1960s to detail international food legislation
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Environmental Medicine Commentary(Berg and Licht 2002). In 2000, the Codex
Committee for Food Additives and
Contaminants (CCFAC) reached agreement
on the principles for setting maximum limits
(MLs) for contaminants (Codex Alimentarius
Commission 2000). MLs were proposed for
lead and Cd in various food categories,
including peanuts and bivalve mollusks,
which have been traded internationally (Berg
and Licht 2002). At the 35th CCFAC meet-
ing in 2003, the proposed draft of MLs for
Cd in rice, soybean, mollusks, and peanuts
(Codex Alimentarius Commission 2003) was
circulated to Codex member countries and
international organizations for additional
consideration and comments.
Bivalve mollusks and crustaceans are
known to have the ability to accumulate Cd
from the aquatic environment, and their Cd
contents are usually > 1–2 mg/kg ww (Kikuchi
et al. 2002; Kruzynski 2004; Storelli and
Marcotrigiano 2001). Such high Cd concen-
trations in the mollusks and crustaceans have
raised considerable concerns for frequent con-
sumers whose dietary Cd intake easily exceed
the PTWI for Cd (Kruzynski 2004). The
European Community has set the ML for Cd
in bivalve mollusks at 1 mg/kg ww (1 ppm),
and Australia, New Zealand, and Hong Kong
have an ML for Cd in mollusks of 2 ppm
(Codex Alimentarius Commission 2000).
Canada and the United States have not estab-
lished ML values for Cd.
Estimated dietary Cd intakes vary widely
in different countries. Most of such esti-
mates show that intakes were within the
PTWI. In European countries, dietary Cd
intake estimates were between 10 and
30 µg/day, corresponding to 17–50% of the
PTWI (Nasreddine and Parent-Massin 2002).
In Australia, a dietary Cd intake of 7–9 µg/day
was derived from the food Cd content data-
base and national consumption data, but the
measured levels of Cd accumulation in kid-
neys of Australians suggest greater dietary Cd
intake of 20–30 µg/day (Satarug et al. 2002,
2003). Approximately two-thirds of dietary
Cd intake is derived from plant products, and
animal products provide the remaining one-
third of total Cd intake. Because foodstuffs
are the main source of human intake of Cd,
greater efforts need to be made to reduce
exposure to dietary Cd. Thus, the maximum
level for Cd in a foodstuff should be set as low
as reasonably achievable. Attempts to reduce
human exposure to dietary Cd by risk reduc-
tion measures supported by international leg-
islation (ML) should not be relaxed. Efforts
should continue toward better agricultural
practices such as defining the areas, culture
methods, species, and harvest times that
would minimize Cd residues. There is no dis-
tinction between toxicity of natural or anthro-
pogenic Cd.
Enteral versus Pulmonary Cd
Absorption
The dietary Cd absorption rate in humans has
been estimated at 5% (IPCS 1992; WHO
1989). However, interindividual variation in
Cd absorption has been shown to be much
greater than the previous estimate; Cd absorp-
tion rates increase to 20–30% in some indi-
viduals (Kikuchi et al. 2003; Satarug et al.
2004). The metal transporter protein
Nramp2, known also as DMT1, has been
shown to be involved in Cd absorption
(Tallkvist et al. 2001). Increased expression of
the intestinal DMT1 was found in iron deﬁ-
ciency and hemochromatosis (Zoller et al.
1999, 2001). Increased expression of the metal
transporter protein DMT1, in general, would
provide individuals with a greater capacity to
absorb Fe and possibly Cd. This provides a
likely explanation for a 3.4-fold increase in Cd
body burden in women with low Fe stores
seen in our recent study on Thai subjects
(Satarug et al. 2004). Olsson et al. (2002) also
observed an increased rate of Cd absorption in
individuals with low body Fe stores. Thus,
special consideration should be given to ensure
adequate Fe intakes to reduce Cd absorption.
In addition to increased dietary Cd absorption
and Cd load, there is evidence for increased
sensitivity to Cd toxicities in women (Nishijo
et al. 2004; Vahter et al. 2002).
Cd is an integral constituent of tobacco
because of the propensity of the Nicotiana
species to concentrate Cd independent of
soil-Cd content. Tobacco Cd content varies
widely, but a typical range is 1–2 µg/g dry
weight, equivalent to 0.5–1 µg/cigarette. Cd
oxide generated during the burning of ciga-
rettes is highly bioavailable. Approximately
10% of the inhaled Cd oxide is deposited in
lung tissues, and another 30–40% is absorbed
into systemic blood circulation of smokers.
Smokers have 4–5 times higher Cd levels in
blood and 2–3 times greater amounts of Cd
in their kidneys than do nonsmokers.
Adverse Health Effects of
Chronic Cd Intake
Cd and chronic (end-stage) renal failure.
Hellstrom et al. (2001) determined the inci-
dence of end-stage renal disease in a Swedish
population using data from individuals under-
going renal replacement therapy (RRT). The
age-standardized rate ratio for RRT was, respec-
tively, 1.4, 1.9, and 2.3, in low-, moderate-,
and high-exposure groups, deﬁned by employ-
ment history together with distance of resi-
dence from a Cd battery plant. Workers in the
Cd battery plant or the residents of Cd-pol-
luted areas near the plant comprised the high-
exposure group, whereas those residing < 2 km
or between 2 and 10 km from the plant com-
prised the moderate-exposure and low-expo-
sure groups, respectively. The rate ratio for
RRT in women was 2.3; this value was higher
than the RRT rate ratio of 1.5 in men of the
same age (Hellstrom et al. 2001). Cd levels in
RRT patients were not determined, but the
Cd urinary excretion of approximately 1 µg/g
creatinine derived from residents of contami-
nated areas in Sweden suggests intake of less
than the PTWI. Thus, Cd exposure, even at
levels lower than the PTWI, may contribute
to chronic renal failure, which occurred at a
higher rate in women than in men of the same
age and area (Hellstrom et al. 2001).
Cd and bone fragility. In a cross-sectional
study in Belgium, Buchet et al. (1990)
observed that urinary calcium excretion rose by
10 mg/day for every 2-fold increment in uri-
nary Cd excretion. Jarup et al. (1998) reported
that urinary Ca excretion was increased by
90% in Swedish women 50–70 years of age
whose urinary Cd excretion exceeded 1 µg/g
creatinine. In a Chinese population including
residents from low- and high-exposure areas
based on Cd concentrations in rice of
0.07 mg/kg and 3.71 mg/kg, respectively, Wu
et al. (2001) observed that the prevalence of
calciuria was increased by 10% in subjects
whose urinary Cd excretion exceeded 2 µg/g
creatinine. These findings have led to the
hypothesis that prolonged urinary Ca loss
caused by Cd is sufﬁcient to promote skeletal
demineralization, which may lead to increases
in bone fragility and risk of fractures.
A prospective study in Belgium. In a
prospective study (median follow-up of
6.6 years) of a Belgian population, Staessen
et al. (1999) observed a 2-fold increase in uri-
nary Cd correlated with a 0.01-g/cm2
decrease in bone density (p < 0.02) in post-
menopausal women. The risks associated with
doubled urinary Cd were 1.73 (p = 0.007) for
fractures in women and 1.60 (p = 0.08) for
height loss in men. Mean urinary Cd excre-
tion at baseline of 1 µg/day suggests that Cd
intake did not exceed the PTWI. Thus,
chronic exposure to low-level Cd increases
bone fragility and risk of fractures in women,
despite the nonsignificant change in men.
These female-linked effects are consistent
with the previously described studies linking
Cd absorption with reduced Fe stores.
Cross-sectional studies in Japan and
China. Honda et al. (2003) used a calcaneal
bone stiffness index to estimate bone density
mass of a group of adult Japanese women
whose mean (range) of urinary Cd concentra-
tion was 2.87 (0.25–11.4) µg/g creatinine.
Bone density mass showed an inverse correla-
tion with urinary Cd, after adjusting for age,
body weight, and menstrual status. A 2-fold
increase in urinary Cd was accompanied by a
decrease in bone density mass equivalent to a
1.7-year increase in age. However, the authors
found no correlation between bone mass and
kidney dysfunction as assessed by urinary
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N-acetyl-β-D-glucosaminidase. This suggests
that Cd may produce a primary bone effect
independent from its kidney effects. Ikeda
et al. (2000) reported geometric mean concen-
trations for Cd intake, derived from food
duplicates, and urine samples of 24.7 µg/day
(40% from rice) and 3.94 µg/g creatinine,
respectively. It is reasonable to infer from these
data that Cd intake of the Japanese subjects
(Honda et al. 2003) was within the PTWI.
Aoshima et al. (2003) observed a correla-
tion between renal and bone effects in a group
of Japanese women whose mean (range) of
urinary Cd excretion was 17.2 (5.7–37) µg/g
creatinine. These concentrations were higher
than those reported by Honda et al. (2003).
Serum markers of bone formation, but not
urinary markers of bone resorption, showed
correlation with Cd-related renal tubular dys-
function assessed by glomerular ﬁltration rate
and fractional excretion rates for β2-MG.
Thus, bone formation might be affected by
renal tubular dysfunction induced by Cd.
Nordberg et al. (2002) recorded mean uri-
nary Cd excretion values of 14.5, 4.8, and
2.4 µg/g creatinine for Chinese subjects living
in areas with high, moderate, and low (con-
trol) Cd pollution areas, respectively. Based on
rice Cd content, average total Cd intakes of
these subjects in the high and moderate pollu-
tion areas and the control areas were 545, 106,
and 22 mg, respectively (Jin et al. 2002).
These concentrations were lower than a
2,000-mg lifetime cumulative exposure limit
(WHO 1989), but decreased bone density was
found in postmenopausal women with ele-
vated urinary Cd excretions or blood Cd and
among men with elevated blood Cd (Jin et al.
2002). This Chinese study suggests a link
between kidney and bone toxicities, which was
not evident in the Japanese study by Honda
et al. (2003). The reasons for the discrepancies
are not known, but it may be related to
genetic differences in kidney sensitivity to Cd
or to higher levels of protective factors, such as
vitamin C status, in Japanese subjects com-
pared to Chinese subjects. It may also be due
to higher Cd internal doses in Chinese sub-
jects than in Japanese subjects. Kobayashi
et al. (2002) provided a thorough analysis of
total Cd intake and relative risk estimates of
adverse renal effects.
Cross-sectional studies in Sweden. In a
study in Sweden, Alfven et al. (2000) found
inverse relationships between urinary Cd
excretion and tubular proteinuria, and forearm
bone mineral density (BMD). This was partic-
ularly apparent in the subjects older than
60 years. The odds ratios (ORs) for osteo-
porosis in men were 2.2 in the medium-dose
group (0.5–3 µg Cd/g creatinine) and 5.3 in
the highest dose group (≥ 3µ g Cd/g creati-
nine) compared with the lowest dose group
(< 0.5 µg Cd/g creatinine). For women, the
OR for osteoporosis was 1.8 in the medium-
dose group, but the OR for osteoporosis could
not be determined for women in the highest
dose group because no women excreted urinary
Cd at levels ≥ 3µ g Cd/g creatinine.
In another study, Alfven et al. (2002)
reported that the group with the highest blood
Cd levels (≥ 1µ g/L) had a 4-fold greater risk
of having renal dysfunction (proteinuria) com-
pared with the group with the lowest blood
Cd levels (≤ 0.5 µg/L). In the older age group
(> 60 years), the risk of low BMD for the
group with the highest blood Cd was 3-fold
greater than that for the group with the lowest
blood Cd levels. Blood Pb levels did not corre-
late with proteinuria or BMD.
Cd and reproductive outcomes. There is
abundant literature on effects of smoking on
pregnancy outcome, for example, early deliv-
ery and low birth weight. However, Cd expo-
sure data were lacking in those early studies to
reveal association between the maternal Cd
exposure from smoking and adverse pregnancy
outcomes, given the fact that cigarette smoke
contains more than 3,000 substances, includ-
ing the metallic elements Cd, Pb, nickel, and
cobalt. The result of the study by Nishijo et al.
(2002) suggested that there is a relationship
between maternal Cd exposure and adverse
reproductive outcomes, akin to the effects of
smoking. Preterm and cesarean section deliv-
eries were found to occur approximately
4 times more frequently in women with
higher Cd burdens (urinary Cd ≥ 2µ g/g crea-
tinine) than in those with lower Cd burdens
(urinary Cd < 2 µg/g creatinine). In addition,
Nishijo et al. (2002) found an inverse correla-
tion between maternal urinary Cd excretion
and gestational age, after adjustment for
maternal age. The height and weight of the
infants of women in the higher urinary Cd
group were significantly lower than those of
infants of women with lower urinary Cd. The
smaller size of infants was attributed to early
delivery, possibly induced by Cd. No correla-
tion was evident between fetal development
and maternal Cd exposure. This is consistent
with data on neonatal Cd content revealed by
a British study in which liver samples collected
at autopsy from 157 subjects, < 1 day to
6 years of age showed that liver Cd levels are
negligible in neonates but increased in older
children (Lyon et al. 2002). The negligible
amounts of Cd in neonatal liver provide
direct evidence that Cd does not cross the
human placental barrier, and hence the fetus
seems to be well protected from Cd exposure
in utero. However, Cd exposure in the United
Kingdom (Lyon et al. 2002) was much lower
than in Japan (Nishijo et al. 2002).
Cd in breast milk. Nishijo et al. (2002)
reported that Cd concentrations in breast
milk from women in their higher and lower
Cd exposure groups were 0.52 µg/L and
0.31 µg/L, respectively. They observed a posi-
tive correlation between maternal Cd burden
and breast milk Cd concentration. This corre-
lation was confirmed in a subsequent study
involving analysis of Cd in urine and in breast
milk samples collected 5–8 days postpartum
(Honda et al. 2003). Cd in breast milk
reflected maternal Cd exposure. Further
analysis of breast milk samples for Ca, zinc,
copper, magnesium, sodium, potassium, and
phosphorus revealed an inverse correlation
between Cd and Ca in breast milk, suggesting
that higher levels of Cd result in lower levels
of Ca in breast milk. Implications of early-life
Cd exposure warrant further research; a study
in rats revealed that exposure to Cd in early
life resulted in rapid weight gain and early
onset of puberty (Johnson et al. 2003).
Cd and human cancers. Cd in respirable
forms was classiﬁed as a cancer-causing agent
in humans by the WHO (1993), based on
consistent reports of an association between Cd
exposure and lung cancer (IARC 1993). This
is supported by a study in rats in which Cd
exposure by inhalation resulted in pulmonary
cancer (Waalkes 2003). It is noteworthy that
Cd displays multitissue carcinogenicity in rats
and that cigarette smoking, which provides a
substantial additional source of Cd, has been
identified as a risk factor in many common
human cancers. Thus, the possibility that Cd is
involved in cancers at other sites cannot be
excluded, given the long residence time of Cd
in tissues and organs.
Renal cell cancer. Pesch et al. (2000)
found that excess risks for renal cell cancer
after high exposure to Cd were greater in
women (OR = 2.6) than in men (OR = 1.4).
This suggests a high susceptibility of female
kidneys to Cd carcinogenesis. This observa-
tion could be predicted because the rate of
uptake and tissue accumulation of Cd in
women is higher than in men, as discussed
above. An association between renal cancer
and Cd exposure was also seen by Hu et al.
(2002) using questionnaire data from histo-
logically conﬁrmed cases and population con-
trols in eight Canadian provinces. The authors
observed a borderline signiﬁcant increased risk
of renal cancer associated with duration of Cd
exposure (OR = 1.9) only in men. This
Canadian survey could not establish the asso-
ciation between Cd exposure and renal cancer
in women because of the small number of
women who had been exposed to Cd.
Breast cancer. Band et al. (2002) found
that the risk of breast cancer (OR = 1.69)
was increased in women who had been preg-
nant and who had started smoking within
5 years of menarche. The risk rose sharply in
nulliparous women who smoked ≥ 20 ciga-
rettes daily (OR = 7.08) and had smoked for
≥ 20 cumulative pack-years (OR = 7.48).
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ing prevention (low Cd exposure) in early
adolescence. In support of a potential role for
Cd exposure in breast cancer, Cd has been
shown to mimic estrogenic effects in breast
tissues of rats (Johnson et al. 2003). In
Cd-exposed female rats, mammary glands
were larger than those of unexposed rats.
These changes were also seen in rats whose
endogenous estrogen sources (ovaries) had
been removed (Johnson et al. 2003).
Prostate and colorectal cancers. Exposure
to Cd is one of the identified risk factors of
prostate cancer together with obesity and con-
sumption of animal fat and red meat, whereas
vegetable and cereal consumption and vita-
min D are protective factors (Ekman 1999);
high blood vitamin D3 concentrations were
associated with lowered prostate cancer risk.
A certain genetic variant of vitamin D recep-
tor has been associated with a 4.6-fold greater
risk of prostate cancer compared with the
wild-type receptor (Ingles et al. 1997). Of rel-
evance, Cd exposure has been shown to inter-
fere with renal vitamin D3 synthesis (Chalkley
et al. 1998). Consistent with carcinogenicity
of Cd, human prostate epithelial cells trans-
formed to cancer cells after repeated Cd expo-
sure (Achanzar et al. 2001; Nakamura et al.
2002). As with prostate cancer, vitamin D has
been found to be a protective factor against
colorectal cancer (Lamprecht and Lipkin
2003), whereas cigarette smoking is one of
the risk factors, although involvement of Cd
has never been investigated. Colorectal cancer
is a major type of cancer seen in people with
genetic defects in the mismatch repair system.
Interestingly, Jin et al. (2003) reported a
2,000-fold increase in the gene mutation rate
in yeast cells whose DNA-mismatch repair
mechanism was suppressed by low-level Cd.
Exposure of colon cells to bile and fecal Cd
thus may contribute to the development of
colorectal cancer in some individuals whose
diets contain high Cd.
Conclusion
Cd remains an environmental pollutant of
continuing concern. Dose–response analyses
and risk estimates indicate that adverse health
outcomes due to chronic Cd exposure occur
at renal concentrations that are much lower
than the previous estimate of 180–200 µg/g
kidney cortex and at intake levels lower than
the current PTWI. In addition, Cd-linked
toxicities are found more frequently in
women than in men. High rates of soil-to-
plant transfer of Cd coupled with continuing
mobilization of small amounts of the metal
from nonbioavailable geologic matrices into
biologically accessible situations predicts that
human exposure to dietary Cd will gradually
increase in the next 10–20 years. There is a
lack of therapeutically effective chelating
agents to reduce Cd burden, and this factor
makes exposure minimization pivotal. The
persistence in the environment of this metal
requires a long-term approach to minimizing
human exposure through environmental
management and maintenance of lower Cd
levels wherever possible. International food
legislation, through setting the ML for a
cumulative toxin such as Cd in agricultural
products, is one of the strategies for exposure
minimization.
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